BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$70.10 USD
-0.19 (-0.27%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $70.22 +0.12 (0.17%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$70.10 USD
-0.19 (-0.27%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $70.22 +0.12 (0.17%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth B Momentum B VGM
Zacks News
Biotech Stock Roundup: Cara Plunges on Study Data, Regulatory Updates & More
by Arpita Dutt
Key highlights in the biotech sector include mixed data from Cara (CARA) and regulatory updates from companies like BioMarin.
BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase
by Zacks Equity Research
BioMarin Pharmaceutical Inc. (BMRN) announced that it has filed a biologics license application (BLA) with the FDA for its pipeline candidate, pegvaliase for phenylketonuria (PKU).
Why is Catalyst Pharmaceuticals' Stock Up 160% this Year?
by Zacks Equity Research
Shares of Catalyst Pharmaceuticals, Inc. (CPRX) have soared 161% this year so far, massively outperforming the Zacks classified Medical Drugs industry's gain of 10.2%.
BioMarin (BMRN) in Focus: Stock Moves 7% Higher
by Zacks Equity Research
BioMarin (BMRN) was a big mover last session, as the company saw its shares rise 7% on the day.
BioMarin (BMRN) Down 8% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioMarin's (BMRN) Brineura Approved by European Commission
by Zacks Equity Research
BioMarin Pharmaceutical Inc. (BMRN) announced that the European Commission has approved Brineura (cerliponase alfa) for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2).
Ultragenyx Receives Priority Review for rhGUS from FDA
by Zacks Equity Research
The FDA has accepted Ultragenyx Pharmaceutical Inc. (RARE)'s BLA for rhGUS on a priority review basis and set a PDUFA action date of Nov 16, 2017.
BioMarin (BMRN) Posts Earnings in Q1, Sales Top, Stock Up
by Zacks Equity Research
BioMarin Pharmaceutical Inc. (BMRN) reported earnings of 3 cents per share in the first quarter of 2017.
New Strong Buy Stocks for May 5th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
Why Earnings Season Could Be Great for BioMarin (BMRN)
by Zacks Equity Research
BioMarin (BMRN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Biotech Stock Roundup: Amgen, Gilead, Celgene Q1 Earnings, Sunesis Down on Vosaroxin Update
by Arpita Dutt
Earnings were in focus this week with companies like Amgen (AMGN), Celgene, Vertex, AbbVie, Alexion and Gilead all reporting results over the last few days.
What Lies Ahead for Stericycle (SRCL) this Earnings Season?
by Zacks Equity Research
Waste management firm Stericycle, Inc. (SRCL) is scheduled to report first-quarter 2017 results after the closing bell on May 4.
Agios Pharmaceuticals (AGIO) Q1 Earnings: What's in Store?
by Zacks Equity Research
Agios Pharmaceuticals, Inc. (AGIO) is scheduled to report first-quarter results on May 4 before market open.
BioMarin (BMRN) Q1 Earnings: Will it Beat Estimates Again?
by Zacks Equity Research
We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports first-quarter 2017 results on May 4, after the market closes.
Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug
by Arpita Dutt
Focus this week remained on Biogen's (BIIB) first quarter results which surpassed expectations.
Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed
by Arpita Dutt
Incyte's (INCY) shares were hit by the FDA's complete response letter (CRL) for the company's rheumatoid arthritis drug.
5 Drug Stocks That Could Be Big Winners this Earnings Season
by Arpita Dutt
Here is a look at five companies including Pfizer (PFE) that sport a favorable Zacks Rank and have a positive earnings ESP.
4 FDA Decisions to Watch Out for in Apr 2017
by Arpita Dutt
Companies like BioMarin (BMRN), Roche and Takeda among others have regulatory decisions scheduled for this month.
Why Is BioMarin (BMRN) Down 2.2% Since the Last Earnings Report?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse
by Zacks Equity Research
We issued an updated research report on Catalyst Pharmaceuticals, Inc. (CPRX) on Mar 22.
Repros (RPRX) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Repros Therapeutics Inc. (RPRX) is expected to report fourth-quarter 2016 results this month.
Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report fourth-quarter 2016 results this month.
Inovio (INO): What's in the Cards this Earnings Season?
by Zacks Equity Research
Inovio Pharmaceuticals, Inc. (INO) is expected to report fourth-quarter 2016 results this month. The company incurred wider-than-expected loss in the last quarter.
BioDelivery (BDSI): What's in Store this Earnings Season?
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) is expected to report fourth-quarter 2016 results on Mar 17, before the opening bell. Last quarter, the company???s loss was wider than expected.
What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?
by Zacks Equity Research
Merck KGaA (MKGAF) is scheduled to report fourth-quarter 2016 earnings results on Mar 9.